Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2026-06-05 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
Update zu innovativem Arzneimittel | Kexing Biopharm nimmt ersten Studienteilnehmer in die in China durchgefuhrte klinische Phase-I-Studie mit dem innovativen ophthalmologischen Arzneimittel GB10 auf
Regulatory Filings Classification · 85% confidence The document is a press release/corporate news update announcing the initiation of a Phase I clinical study for a new ophthalmological drug. It contains no financial results, no reference to an AGM or shareholder vote, no capital changes, no legal proceedings, and no detailed financial statements. It is a general corporate announcement distributed via EQS, fitting the ‘Regulatory Filings’ (RNS) fallback category for miscellaneous corporate news. It is not a report itself, nor a mere ‘Report Publication Announcement,’ but a routine regulatory news disclosure.
2026-06-05 German
Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
Regulatory Filings Classification · 45% confidence The document is a corporate press release detailing the enrollment of the first subject in a Phase I clinical trial for an innovative drug. It contains no financial statements, no shareholder voting, no dividends, no management changes, no merger or acquisition information, nor any substantive financial data. It is a general corporate/operational update distributed via PR Newswire/EQS. As such, it does not fit any specialized financial or regulatory report category and falls under the fallback catch-all for miscellaneous regulatory announcements.
2026-06-04 English
关于参加2026年山东辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 50% confidence The document is an announcement about the company’s participation in a regulator-organized online investor reception day event. It contains no financial statements, votes, or executive changes, nor does it present or attach a report. This type of general corporate/ regulatory disclosure falls under the fallback category “Regulatory Filings” (RNS).
2026-05-12 Chinese
关于向香港联交所递交H股发行并上市申请的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company about the progress of its application to issue H shares and list on the Hong Kong Stock Exchange. It mentions submission of application materials and provides links to the application documents on the exchange's website. The text explicitly states that this announcement is to inform domestic investors about the listing progress and that the application materials are draft versions subject to updates. There is no financial data, no detailed report content, and the document is relatively short (1083 characters). It is clearly an announcement about a capital market event (H-share issuance and listing application progress), not the actual issuance or financial report. Therefore, this fits best as a Capital/Financing Update (CAP) filing type, which covers updates on company fundraising and capital structure changes.
2026-05-07 Chinese
2025年度独立董事述职报告（何如意）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 from a company. It details the independent director's background, attendance at board and committee meetings, exercise of duties, oversight of financial reports, internal controls, audit firm appointment, management appointments, and overall evaluation and suggestions. The content focuses on the independent director's activities and governance oversight during the year, rather than presenting full financial statements or comprehensive company financial performance. It is a governance-related report describing the independent director's role and work, not an annual report or audit report itself. Therefore, it fits best under Board/Management Information (MANG), which includes announcements or reports about board or senior management activities and changes. The document length is about 4785 characters, which is sufficient for a detailed report but not a full annual report. No financial statements or detailed financial data are included, so it is not a 10-K or IR. It is not a proxy, remuneration, or governance rules report. Hence, the classification is MANG with high confidence.
2026-04-21 Chinese
2025年度募集资金存放、管理与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2025年度募集资金存放、管理与实际使用情况的专项报告" which translates to a "Special Report on the Deposit, Management, and Actual Use of Raised Funds for the Year 2025." It details the company's fundraising activities, including the amount raised, usage, management, and changes in the use of raised funds. It includes tables showing the raised funds' storage, usage, and changes in investment projects. The document also contains opinions from the accounting firm and sponsors on the compliance and proper use of the raised funds. The content is focused on the management and use of capital raised from a public offering, which aligns with a Capital/Financing Update. The document is substantive and detailed, not merely an announcement or certification. Therefore, it fits best under the Capital/Financing Update (CAP) category.
2026-04-21 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.